Hoʻonui ʻia ka maikaʻi o ka antitumor o 4-1BB-Based CD19 CAR-T Cells i ka mālama ʻana i ka B-ALL

I loko o kahi noiʻi koʻikoʻi koʻikoʻi i mālama ʻia e ka Halemai Lu Daopei a me Lu Daopei Institute of Hematology, ua ʻike nā mea noiʻi he 4-1BB-based CD19 CAR-T cell e hāʻawi i kahi koho ʻē aʻe i ka CD28-based CAR-T cell no ka mālama ʻana i ka relapsed a refractory. B cell acute lymphoblastic leukemia (r/r B-ALL). ʻO kēia haʻawina, e pili ana i nā noiʻi noiʻi pre-clinical a me ka exploratory clinical investigations, ua hōʻike ʻo 4-1BB CAR-T cell ʻaʻole wale e hāʻawi i kahi kiʻekiʻe antitumor efficacy akā hōʻike pū kekahi i ka lōʻihi o ka hoʻomau ʻana i nā maʻi i hoʻohālikelike ʻia i kā lākou mau hoa CD28.

Ua hoʻohālikelike ka hui noiʻi o ka Halemai ʻo Lu Daopei i ka hana o kēia mau ʻano cell CAR-T ʻelua. Ua ʻike lākou, ma lalo o ke kaʻina hana like, ʻoi aku ka ikaika o nā pūnaewele CAR-T 4-1BB i ka hopena antitumor i nā haʻahaʻa haʻahaʻa a ua liʻiliʻi nā hopena koʻikoʻi ma mua o nā cell CD28 CAR-T. Hōʻike nā hopena o ke aʻo ʻana e hāʻawi paha ka lāʻau lapaʻau CAR-T i 4-1BB i kahi koho lapaʻau ʻoi aku ka maikaʻi a palekana no nā poʻe maʻi e loaʻa ana i ka r/r B-ALL.

Hōʻike kēia mau ʻike i ka hoʻokō ʻana o ka Halemai Lu Daopei i ka holomua ʻana o ka hematology a me ka immunotherapy, e hāʻawi ana i ka manaʻolana i nā poʻe maʻi i pane ʻole i ka mālama maʻamau. ʻO ke aʻo ʻana, ka mea i hahai i nā kūlana koʻikoʻi koʻikoʻi a loaʻa ka ʻae ʻia mai ke Kōmike Hoʻonaʻauao Halemai ʻo Lu Daopei, e hoʻoikaika ana i ke kuleana o ka haukapila i ke alakaʻi ʻana i ka noiʻi hou i nā lāʻau lapaʻau CAR-T.

Me kēia holomua, ke hoʻomau nei ka Lu Daopei Institute of Hematology i nā palena hou i ka noiʻi olakino, e hāʻawi ana i nā koho lapaʻau ʻokiʻoki a me ka hoʻomaikaʻi ʻana i nā hopena maʻi. He hōʻike kēia holomua i ka hoʻolaʻa a me ke akamai o nā hui lapaʻau a me nā hui noiʻi o ka Halemai Lu Daopei.